Sharma, Akshay and Galimard, Jacques-Emmanuel and Pryce, Angharad and Bhoopalan, Senthil Velan and Dalissier, Arnaud and Dalle, Jean-Hugues and Locatelli, Franco and Jubert, Charlotte and Mirci-Danicar, Oana and Kitra-Roussou, Vassiliki and Bertrand, Yves and Fagioli, Franca and Rialland, Fanny and Biffi, Alessandra and Wynn, Robert F. and Michel, Gerard and Tambaro, Francesco Paolo and Al-Ahmari, Ali and Tbakhi, Abdelghani and Furness, Caroline L. and Diaz, Miguel Angel and Sedlacek, Petr and Bodova, Ivana and Faraci, Maura and Rao, Kanchan and Kleinschmidt, Katharina and Petit, Arnaud and Gibson, Brenda and Bhatt, Neel S. and Kalwak, Krzysztof and Corbacioglu, Selim (2024) Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study. BONE MARROW TRANSPLANTATION, 59 (4). pp. 451-458. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic stem cell transplant (HSCT). We assessed the predictive value of cytogenetic risk classification at diagnosis with respect to post-HSCT outcomes in pediatric patients. Patients younger than 18 years at the time of their first allogeneic HSCT for AML in CR1 between 2005 and 2022 who were reported to the European Society for Blood and Marrow Transplantation registry were subgrouped into four categories. Of the 845 pediatric patients included in this study, 36% had an 11q23 abnormality, 24% had monosomy 7/del7q or monosomy 5/del5q, 24% had a complex or monosomal karyotype, and 16% had other PR cytogenetic abnormalities. In a multivariable model, 11q23 (hazard ratio [HR] = 0.66, P = 0.03) and other PR cytogenetic abnormalities (HR = 0.55, P = 0.02) were associated with significantly better overall survival when compared with monosomy 7/del7q or monosomy 5/del5q. Patients with other PR cytogenetic abnormalities had a lower risk of disease relapse after HSCT (HR = 0.49, P = 0.01) and, hence, better leukemia-free survival (HR = 0.55, P = 0.01). Therefore, we conclude that PR cytogenetic abnormalities at diagnosis predict overall survival after HSCT for AML in pediatric patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BONE-MARROW-TRANSPLANTATION; 1ST REMISSION; HEMATOLOGIC MALIGNANCIES; PROGNOSTIC-SIGNIFICANCE; COMPARABLE SURVIVAL; REDUCED INTENSITY; DE-NOVO; T-CELL; AML; IMPACT; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 06 Aug 2025 06:19 |
| Last Modified: | 06 Aug 2025 06:19 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65689 |
Actions (login required)
 |
View Item |
